Use of BRAF v600e immunocytochemistry on FNA direct smears of papillary thyroid carcinoma

Cancer Cytopathology

Volumn 123, Issue 9, 2015, Pages 531-539

  Wobker, Sara E ^a   Kim, Lawrence T ^a   Hackman, Trevor G ^a   Dodd, Leslie G ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

BRAF protein; fine needle aspiration; human; immunohistocytochemistry; papillary thyroid carcinoma; thyroid gland

Indexed keywords

B RAF KINASE; BRAF PROTEIN, HUMAN;

ARTICLE; BRAF GENE; CONTROLLED STUDY; FALSE NEGATIVE RESULT; FINE NEEDLE ASPIRATION BIOPSY; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SMEAR; THYROID PAPILLARY CARCINOMA; AGED; CARCINOMA; EPIDEMIOLOGY; FEMALE; GENETICS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROCEDURES; RETROSPECTIVE STUDY; THYROID NEOPLASMS; THYROIDECTOMY; UNIVERSITY HOSPITAL;

AGED; BIOPSY, FINE-NEEDLE; CARCINOMA; DNA MUTATIONAL ANALYSIS; FEMALE; HOSPITALS, UNIVERSITY; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROTO-ONCOGENE PROTEINS B-RAF; RETROSPECTIVE STUDIES; SAMPLING STUDIES; SENSITIVITY AND SPECIFICITY; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 84952050257     PISSN: 1934662X     EISSN: 19346638     Source Type: Journal    
DOI: 10.1002/cncy.21575     Document Type: Article

References (48)

1. Siegel R, Ma J, Zou Z, Jemal A,. Cancer statistics, 2014. CA Cancer J Clin. 2014; 64: 9-29.
2. Ali SZ, Cibas ES, eds. The Bethesda System for Reporting Thyroid Cytopathology. New York: Springer; 2010.
3. Raab SS, Vrbin CM, Grzybicki DM, et al., Errors in thyroid gland fine-needle aspiration. Am J Clin Pathol. 2006; 125: 873-882.
4. Ylagan LR, Farkas T, Dehner LP,. Fine needle aspiration of the thyroid: a cytohistologic correlation and study of discrepant cases. Thyroid. 2004; 14: 35-41.
5. Bakhos R, Selvaggi SM, DeJong S, et al., Fine-needle aspiration of the thyroid: rate and causes of cytohistopathologic discordance. Diagn Cytopathol. 2000; 23: 233-237.
6. Xing M,. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev. 2007; 28: 742-762.
7. Caronia LM, Phay JE, Shah MH,. Role of BRAF in thyroid oncogenesis. Clin Cancer Res. 2011; 17: 7511-7517.
8. Soares P, Trovisco V, Rocha AS, et al., BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene. 2003; 22: 4578-4580.
9. Xing M, Alzahrani AS, Carson KA, et al., Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. J Clin Oncol. 2015; 33: 42-50.
10. Long GV, Wilmott JS, Capper D, et al., Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma. Am J Surg Pathol. 2013; 37: 61-65.
11. Routhier CA, Mochel MC, Lynch K, Dias-Santagata D, Louis DN, Hoang MP,. Comparison of 2 monoclonal antibodies for immunohistochemical detection of BRAF V600E mutation in malignant melanoma, pulmonary carcinoma, gastrointestinal carcinoma, thyroid carcinoma, and gliomas. Hum Pathol. 2013; 44: 2563-2570.
12. Ilie MI, Lassalle S, Long-Mira E, et al., Diagnostic value of immunohistochemistry for the detection of the BRAF(V600E) mutation in papillary thyroid carcinoma: comparative analysis with 3 DNA-based assays. Thyroid. 2014; 24: 858-866.
13. Lee SR, Yim H, Han JH, et al., VE1 antibody is not highly specific for the BRAF V600E mutation in thyroid cytology categories with the exception of malignant cases. Am J Clin Pathol. 2015; 143: 437-444.
14. Zimmermann A-K, Camenisch U, Rechsteiner MP, Bode-Lesniewska B, Rössle M,. Value of immunohistochemistry in the detection of BRAF(V600E) mutations in fine-needle aspiration biopsies of papillary thyroid carcinoma. Cancer Cytopathol. 2014; 122: 48-58.
15. Poller DN, Glaysher S,. BRAF V600 co-testing is technically feasible in conventional thyroid fine needle aspiration (FNA) cytology smears and can reduce the need for completion thyroidectomy. Cytopathology. 2014; 25: 155-159.
16. Poller DN, Glaysher S, Agrawal A, Caldera S, Kim D, Yiangou C,. BRAF V600 co-testing in thyroid FNA cytology: short-term experience in a large cancer centre in the UK. J Clin Pathol. 2014; 67: 684-689.
17. Yarchoan M, LiVolsi VA, Brose MS,. BRAF mutation and thyroid cancer recurrence. J Clin Oncol. 2015; 33: 7-8.
18. Rossi M, Buratto M, Tagliati F, et al., Relevance of BRAF(V600E) mutation testing versus RAS point mutations and RET/PTC rearrangements evaluation in the diagnosis of thyroid cancer. Thyroid. 2015; 25: 221-228.
19. Pearlstein MV, Zedek DC, Ollila DW, et al., Validation of the VE1 immunostain for the BRAF V600E mutation in melanoma. J Cutan Pathol. 2014; 41: 724-732.
20. Dvorak K, Aggeler B, Palting J, McKelvie P, Ruszkiewicz A, Waring P,. Immunohistochemistry with the anti-BRAF V600E (VE1) antibody: impact of preanalytical conditions and concordance with DNA sequencing in colorectal and papillary thyroid carcinoma. Pathology. 2014; 46: 509-517.
21. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA,. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003; 63: 1454-1457.
22. Trovisco V, Vieira de Castro I, Soares P, et al., BRAF mutations are associated with some histological types of papillary thyroid carcinoma. J Pathol. 2004; 202: 247-251.
23. Rossi ED, Martini M, Capodimonti S, et al., Analysis of immunocytochemical and molecular BRAF expression in thyroid carcinomas: a cytohistologic institutional experience. Cancer Cytopathol. 2014; 122: 527-535.
24. Falchook GS, Millward M, Hong D, et al., BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer. Thyroid. 2015; 25: 71-77.
25. Dadu R, Shah K, Busaidy NL, et al., Efficacy and tolerability of vemurafenib in patients with BRAF(V600E)-positive papillary thyroid cancer: MD Anderson Cancer Center off label experience. J Clin Endocrinol Metab. 2015; 100: E77-E81.
26. Kim KB, Cabanillas ME, Lazar AJ, et al., Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation. Thyroid. 2013; 23: 1277-1283.
27. McKelvie PA, Chan F, Yu Y, et al., The prognostic significance of the BRAF V600E mutation in papillary thyroid carcinoma detected by mutation-specific immunohistochemistry. Pathology. 2013; 45: 637-644.
28. Rossi ED, Martini M, Capodimonti S, et al., BRAF (V600E) mutation analysis on liquid-based cytology-processed aspiration biopsies predicts bilaterality and lymph node involvement in papillary thyroid microcarcinoma. Cancer Cytopathol. 2013; 121: 291-297.
29. Prescott JD, Sadow PM, Hodin RA, et al., BRAF V600E status adds incremental value to current risk classification systems in predicting papillary thyroid carcinoma recurrence. Surgery. 2012; 152: 984-990.
30. Li C, Lee KC, Schneider EB, Zeiger MA,. BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis. J Clin Endocrinol Metab. 2012; 97: 4559-4570.
31. O'Neill CJ, Bullock M, Chou A, et al., BRAF(V600E) mutation is associated with an increased risk of nodal recurrence requiring reoperative surgery in patients with papillary thyroid cancer. Surgery. 2010; 148: 1139-1145; discussion 1145-1146.
32. Niederer-Wüst SM, Jochum W, Förbs D, et al., Impact of clinical risk scores and BRAF V600E mutation status on outcome in papillary thyroid cancer. Surgery. 2015; 157: 119-125.
33. Nikiforov YE, Ohori NP, Hodak SP, et al., Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab. 2011; 96: 3390-3397.
34. Danilovic DL, Lima EU, Domingues RB, Brandão LG, Hoff AO, Marui S,. Pre-operative role of BRAF in the guidance of the surgical approach and prognosis of differentiated thyroid carcinoma. Eur J Endocrinol. 2014; 170: 619-625.
35. Kleiman DA, Sporn MJ, Beninato T, et al., Preoperative BRAF(V600E) mutation screening is unlikely to alter initial surgical treatment of patients with indeterminate thyroid nodules: a prospective case series of 960 patients. Cancer. 2013; 119: 1495-1502.
36. Gouveia C, Can NT, Bostrom A, Grenert JP, van Zante A, Orloff LA,. Lack of association of BRAF mutation with negative prognostic indicators in papillary thyroid carcinoma: the University of California, San Francisco, experience. JAMA Otolaryngol Head Neck Surg. 2013; 139: 1164-1170.
37. Xing M,. BRAF mutation in thyroid cancer. Endocr Relat Cancer. 2005; 12: 245-262.
38. Frasca F, Nucera C, Pellegriti G, et al., BRAF(V600E) mutation and the biology of papillary thyroid cancer. Endocr Relat Cancer. 2008; 15: 191-205.
39. Kim S, Lee KE, Myong JP, et al., BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer. World J Surg. 2012; 36: 310-317.
40. Lee JH, Lee ES, Kim YS,. Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis. Cancer. 2007; 110: 38-46.
41. Howitt BE, Paulson VA, Barletta JA,. Absence of BRAF V600E in non-infiltrative, non-invasive follicular variant of papillary thyroid carcinoma [published online ahead of print March 4, 2015]. Histopathology. doi: 10.1111/his.12680.
42. Cameselle-Teijeiro J, Ferreira R, Caramés N, et al., Absence of the BRAF and the GRIM-19 mutations in oncocytic (Hürthle cell) solid cell nests of the thyroid. Am J Clin Pathol. 2012; 137: 612-618.
43. Smith RA, Salajegheh A, Weinstein S, Nassiri M, Lam AK,. Correlation between BRAF mutation and the clinicopathological parameters in papillary thyroid carcinoma with particular reference to follicular variant. Hum Pathol. 2011; 42: 500-506.
44. Finkelstein A, Levy GH, Hui P, et al., Papillary thyroid carcinomas with and without BRAF V600E mutations are morphologically distinct. Histopathology. 2012; 60: 1052-1059.
45. Agretti P, Niccolai F, Rago T, et al., BRAF mutation analysis in thyroid nodules with indeterminate cytology: our experience on surgical management of patients with thyroid nodules from an area of borderline iodine deficiency. J Endocrinol Invest. 2014; 37: 1009-1014.
46. Capelli L, Marfisi C, Puccetti M, et al., Role of BRAF molecular analysis in the management of papillary thyroid carcinoma: analysis of cytological and histological samples [published online ahead of print August 14, 2014]. Cytopathology. doi: 10.1111/cyt.12199.
47. Johnson SJ, Hardy SA, Roberts C, Bourn D, Mallick U, Perros P,. Pilot of BRAF mutation analysis in indeterminate, suspicious and malignant thyroid FNA cytology. Cytopathology. 2014; 25: 146-154.
48. Jara SM, Bhatnagar R, Guan H, Gocke CD, Ali SZ, Tufano RP,. Utility of BRAF mutation detection in fine-needle aspiration biopsy samples read as "suspicious for papillary thyroid carcinoma" [published online ahead of print July 3, 2014]. Head Neck. doi: 10.1002/hed.23829.